WORX - Akari Positive Data And Other News: The Good Bad And Ugly Of Biopharma

Akari Therapeutics Releases Positive Top Line Data

Akari Therapeutics (AKTX) reported encouraging results from its Phase 2 study of Nomacopan. The study met its primary endpoint which was related to no drug-related adverse events. The drug candidate was granted Orphan Drug designation by the FDA for the treatment of Bullous Pemphigoid. The company plans to meet the FDA and the European Medicines Agency for discussing pivotal trial design in the third quarter of 2020.

The Phase 2 trial for the drug candidate was fully recruited. It was designed for assessing the potential of